Home › NDC Lookup › RxCUI directory › RxCUI 2591510

Talazoparib 0.5 MG Oral Capsule — RxCUI 2591510

RxNorm drug concept · Semantic clinical drug
RxCUI 2591510 Semantic clinical drug · SCD ● Current RxNorm concept 12 FDA products 12 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2591510
Official nameTalazoparib 0.5 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known astalazoparib 0.5 MG (as talazoparib tosylate 0.727 MG) Oral Capsule
FDA products mapped12
Package NDCs mapped12
Reported Medicaid activity (SDUD)12 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Talazoparib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats adults with BRCA-mutated, HER2-negative advanced breast cancer, used alone. It also treats prostate cancer that has spread and no longer responds to hormone-lowering trea...
  • Swallow Talzenna capsules whole once a day, with or without food. Don't open or dissolve them. If you vomit or miss a dose, just take your next dose at the usual time. Follow your...
  • Tiredness, nausea, vomiting, diarrhea, headache, hair loss and lower appetite are common. Low blood counts are also common, which is why you'll have monthly blood tests. Call your...
  • Check with me or your doctor first. Some drugs, like itraconazole, amiodarone, carvedilol, clarithromycin and verapamil, can raise talazoparib levels. Your dose may need to change...
📖 Read our full Talazoparib guide →

🕸️ Concept Web — How Talazoparib 0.5 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Talazoparib 0.5 MG Oral Capsule RxCUI 2591510

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Talazoparib 2099704
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Talzenna 2099947
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Talazoparib Oral Capsule 2099945
    • Talazoparib Oral Product 2099943
    • Talazoparib Pill 2099944
    • Talazoparib Oral Capsule [Talzenna] 2099949
    • Talzenna Oral Product 2099950
    • Talzenna Pill 2099951
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Talazoparib 0.5 MG SCDC · 2591509
  • Talazoparib Oral Capsule SCDF · 2099945
  • Talazoparib Oral Product SCDG · 2099943
  • Talazoparib Pill SCDG · 2099944

Brand-Name Concepts

  • Talazoparib 0.5 MG Oral Capsule [Talzenna] SBD · 2591512
  • Talazoparib 0.5 MG [Talzenna] SBDC · 2591511
  • Talazoparib Oral Capsule [Talzenna] SBDF · 2099949
  • Talzenna Oral Product SBDG · 2099950
  • Talzenna Pill SBDG · 2099951
  • Talzenna BN · 2099947

📦 FDA Products & Package NDCs

12 products · 12 package NDCs
12 package NDCs map to RxCUI 2591510 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00069-0252-30 30 CAPSULE, LIQUID FILLED in 1 BOTTLE (0069-0252-30) Talzenna Pfizer Laboratories Div Pfizer Inc 2024-04-17
00069-0296-30 1 BOTTLE in 1 CARTON (0069-0296-30) / 30 CAPSULE in 1 BOTTL... Talzenna Pfizer Laboratories Div Pfizer Inc 2018-10-26
00069-0353-30 30 CAPSULE, LIQUID FILLED in 1 BOTTLE (0069-0353-30) Talzenna Pfizer Laboratories Div Pfizer Inc 2024-04-17
00069-0454-30 30 CAPSULE, LIQUID FILLED in 1 BOTTLE (0069-0454-30) Talzenna Pfizer Laboratories Div Pfizer Inc 2024-04-17
00069-0546-30 30 CAPSULE, LIQUID FILLED in 1 BOTTLE (0069-0546-30) Talzenna Pfizer Laboratories Div Pfizer Inc 2024-04-17
00069-0655-30 30 CAPSULE, LIQUID FILLED in 1 BOTTLE (0069-0655-30) Talzenna Pfizer Laboratories Div Pfizer Inc 2024-04-17
00069-0757-30 30 CAPSULE, LIQUID FILLED in 1 BOTTLE (0069-0757-30) Talzenna Pfizer Laboratories Div Pfizer Inc 2024-04-17
00069-1195-30 1 BOTTLE in 1 CARTON (0069-1195-30) / 30 CAPSULE in 1 BOTTL... Talzenna Pfizer Laboratories Div Pfizer Inc 2018-10-26
00069-1501-30 1 BOTTLE in 1 CARTON (0069-1501-30) / 30 CAPSULE in 1 BOTTL... Talzenna Pfizer Laboratories Div Pfizer Inc 2022-01-31
63539-0025-30 30 CAPSULE, LIQUID FILLED in 1 BOTTLE (63539-025-30) Talzenna U.S. Pharmaceuticals 2024-07-09
63539-0031-30 30 CAPSULE, LIQUID FILLED in 1 BOTTLE (63539-031-30) Talzenna U.S. Pharmaceuticals 2024-07-09
63539-0295-30 1 BOTTLE in 1 CARTON (63539-295-30) / 30 CAPSULE in 1 BOTTL... Talzenna U.S. Pharmaceuticals 2018-12-10
Observed labelers: Pfizer Laboratories Div Pfizer Inc (9) · U.S. Pharmaceuticals (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.